Lanreotide Research Peptide (Somatostatin Analog) Supplier — UPOR Biotech
Lanreotide (BIM 23014) — cyclic octapeptide somatostatin analog and high-affinity SST2 receptor agonist. Engineered for prolonged duration of action and greater SST2 selectivity, it suppresses growth hormone (GH), insulin-like growth factor-1 (IGF-1), and neuroendocrine peptide hormone secretion. The reference active principle of Somatuline (lanreotide autogel), supplied as a lyophilized research peptide by UPOR Biotech.
Request a QuoteProduct Overview
Lanreotide (BIM 23014, CAS 108736-35-2, C₅₄H₆₉N₁₁O₁₀S₂, MW 1096.32 g/mol) is a synthetic cyclic octapeptide analogue of somatostatin-14, engineered for higher SST2 receptor selectivity and a markedly prolonged duration of action compared to native somatostatin — which has a plasma half-life of only minutes. Lanreotide acts as a high-affinity agonist at somatostatin receptor subtype 2 (SST2), with lower affinity at SST5. Receptor activation suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion, inhibits the release of serotonin and other neuroendocrine peptide hormones, and slows cell proliferation — the defining pharmacology for acromegaly and neuroendocrine tumor (NET) biology. Structurally, the peptide bears a D-Nal residue at the N-terminus and an intramolecular disulfide bridge that constrains its cyclic octapeptide scaffold, conferring protease resistance and sustained target engagement. UPOR Biotech supplies lanreotide as a white to off-white lyophilized powder, ≥98% HPLC purity, for in vitro and preclinical research.
In endocrinology and oncology research, lanreotide is the reference active principle of Somatuline (lanreotide autogel), the sustained-release somatostatin analogue used clinically for acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET), and carcinoid syndrome. As a leading research peptide supplier, UPOR Biotech provides high-purity lanreotide to academic laboratories, biopharmaceutical discovery teams, and CROs for receptor pharmacology, signal-transduction, and assay-development programs. Certifications include ISO 9001 and cGMP quality systems with FDA facility registration. Lanreotide is supplied for Research Use Only (RUO) — not for human diagnostic or therapeutic use. Packaging is available in 1 mg, 5 mg, 10 mg, and 50 mg lyophilized vials with full lot traceability.
Lanreotide vs Octreotide — Two Somatostatin Analogs for SST2-Mediated Hormone Suppression
Lanreotide and octreotide are the two principal synthetic cyclic somatostatin analogues used to suppress SST2-mediated hormone secretion in acromegaly and neuroendocrine tumors. Lanreotide is the active principle of Somatuline (lanreotide autogel), while octreotide is the active principle of Sandostatin (octreotide LAR). Both are cyclic octapeptides with D-residues and intramolecular disulfide bridges, and both bind SST2 with high affinity. They differ in sustained-release formulation matrix, dosing interval, and minor receptor affinity profiles (lanreotide’s longer terminal half-life supports extended-interval autogel dosing). For researchers dissecting somatostatin receptor pharmacology, lanreotide serves as the key comparator in sustained-release somatostatin analogue therapy — enabling head-to-head study of GH/IGF-1 suppression kinetics, receptor subtype selectivity, and anti-proliferative signaling. UPOR Biotech supplies both peptides strictly as Research Use Only (RUO) reference compounds.
Technical Specifications
| Property | Specification |
|---|---|
| Product Name | Lanreotide Research Peptide (Somatostatin Analog) |
| Synonyms | BIM 23014; Lanreotidum; Somatuline (active principle) |
| CAS Number | 108736-35-2 |
| Molecular Formula | C₅₄H₆₉N₁₁O₁₀S₂ |
| Molecular Weight | 1096.32 g/mol |
| Sequence | H-D-2-Nal-cyclo[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂ |
| Peptide Class | Cyclic octapeptide somatostatin analogue |
| Key Structural Feature | Cyclic scaffold with D-Nal residue at N-terminus and intramolecular disulfide bridge |
| Disulfide Bridge | Cys²–Cys⁷ (intramolecular) — confers protease resistance |
| Mechanism | SST2 receptor agonist (high-affinity) — suppresses GH/IGF-1 and neuroendocrine hormone secretion |
| Receptor Affinity | High affinity SST2; moderate affinity SST5 |
| Purity (HPLC) | ≥98.0% |
| Peptide Content | ≥90% |
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in water, PBS, and buffered saline at neutral pH; reconstitute with sterile water or buffer |
| Endotoxin | ≤1.0 EU/mg |
| Water Content | ≤5.0% |
| Counter-ion | Acetate |
| pH | Neutral (6.0 – 8.0) upon reconstitution |
| Heavy Metals | ≤10 ppm |
| Storage | -20°C, protected from light and moisture; avoid repeated freeze-thaw |
| Grade | Research Grade (RUO) |
| Applications | Acromegaly/GH research; NET studies; somatostatin receptor pharmacology; carcinoid syndrome research; assay development |
| Certifications | ISO 9001, cGMP, FDA facility registration |
| Packaging | 1 mg / 5 mg / 10 mg / 50 mg lyophilized vials |
| Shelf Life | 2 years (stored at -20°C, unopened) |
| Disclaimer | Research Use Only (RUO) — not for human diagnostic or therapeutic use |
Key Benefits — Lanreotide Research Peptide
SST2-Selective Somatostatin Agonism
High-affinity agonist at somatostatin receptor subtype 2 (SST2), with lower affinity at SST5. This subtype selectivity makes lanreotide the reference tool for dissecting SST2-mediated GH/IGF-1 and hormone suppression signaling.
SST2 SelectiveGH & IGF-1 Suppression
Suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion through SST2 activation — the defining pharmacology for acromegaly and somatostatin receptor research.
GH/IGF-1 SuppressionCyclic Octapeptide — Protease-Resistant Scaffold
Constrained cyclic octapeptide with an intramolecular disulfide bridge and D-Nal residue, conferring protease resistance and the prolonged duration of action that distinguishes lanreotide from native somatostatin.
Cyclic Scaffold≥98% HPLC Purity Research Peptide
White to off-white lyophilized powder, ≥98.0% HPLC purity with MS confirmation of molecular weight, endotoxin ≤1.0 EU/mg, and full lot traceability for reproducible preclinical results.
≥98% HPLCApplications
Acromegaly & Growth Hormone Research
Reference peptide for studying SST2-mediated GH and IGF-1 suppression in pituitary cell models and preclinical acromegaly research.
Neuroendocrine Tumor (NET) Studies
Investigating somatostatin analogue effects on GEP-NET hormone secretion, proliferation, and receptor expression.
Somatostatin Receptor Pharmacology
Subtype-selective tool for mapping SST2 vs SST5 signaling, binding affinity, and downstream cAMP/PKA pathways.
Carcinoid Syndrome & Hormone Secretion Research
Studying suppression of serotonin and neuroendocrine peptide hormones in functional tumor models.
Cancer Cell Proliferation & Apoptosis Studies
Evaluating anti-proliferative and pro-apoptotic signaling downstream of SST2 activation in tumor cell lines.
Peptide Reference Standard & Assay Development
High-purity reference standard for HPLC/MS method development, quantification, and receptor binding assays.
Frequently Asked Questions
Lanreotide (BIM 23014, CAS 108736-35-2) is a synthetic cyclic octapeptide analogue of somatostatin-14 engineered for higher SST2 selectivity and prolonged duration of action compared to native somatostatin (half-life of only minutes). It acts as a high-affinity agonist at somatostatin receptor subtype 2 (SST2), with lower affinity at SST5. Receptor activation suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion, inhibits serotonin and other neuroendocrine peptide hormones, and slows cell proliferation — the defining pharmacology of acromegaly and neuroendocrine tumor biology.
Both lanreotide and octreotide are synthetic cyclic somatostatin analogues used for SST2-mediated hormone suppression in acromegaly and neuroendocrine tumors. Lanreotide is the active principle of Somatuline (lanreotide autogel); octreotide is the active principle of Sandostatin (octreotide LAR). They differ in sustained-release formulation, dosing interval, and minor receptor affinity profiles — lanreotide is the key comparator in sustained-release somatostatin analog therapy. UPOR Biotech supplies both as Research Use Only (RUO) reference peptides.
Lanreotide is used in acromegaly and growth hormone research, neuroendocrine tumor (NET) studies, somatostatin receptor (SST2) pharmacology, carcinoid syndrome and hormone secretion research, cancer cell proliferation and apoptosis studies, and as a peptide reference standard in assay development. Its SST2 selectivity makes it a reference tool for dissecting subtype-specific somatostatin receptor signaling and downstream cAMP/PKA pathways.
Store lyophilized lanreotide at -20°C, protected from light and moisture, in a tightly sealed container. For reconstitution, dissolve in sterile water, PBS, or buffered saline at neutral pH and use promptly. Avoid repeated freeze-thaw cycles, which degrade the cyclic octapeptide and disulfide bridge; aliquot reconstituted solutions and store at -20°C for short-term use. Always follow the lot-specific COA and MSDS provided with each shipment.
Every shipment includes a Certificate of Analysis (COA) reporting ≥98.0% HPLC purity, peptide content, endotoxin ≤1.0 EU/mg, water content, counter-ion, and heavy metals; MSDS; HPLC chromatogram; mass spectrometry (MS) confirmation of molecular weight; and residual solvent data. UPOR Biotech operates under ISO 9001 and cGMP quality systems with FDA facility registration. All products are supplied as Research Use Only (RUO) — not for human diagnostic or therapeutic use.